The approval of Yesintek (ustekinumab-kfce), the sixth biosimilar to reference Stelara, will be used to treat patients with ...

The approval marks the sixth biosimilar to reference Stelara (ustekinumab), and it will be used to treat several immunology ...

The Food and Drug Administration (FDA) has approved Yesintek TM (ustekinumab-kfce), a biosimilar to Stelara ® (Ustekinumab), for the treatment of various chronic inflammatory diseases. Yesintek, ...

The US Food and Drug Administration (FDA) has approved ustekinumab -kfce (Yesintek) as a biosimilar to ustekinumab (Stelara) for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis, ...

Biocon Biologics Ltd announced today that the U.S. Food and Drug Administration has approved YESINTEK™ (Ustekinumab-kfce), a ...

Yesintek is the latest Stelara biosimilar to gain FDA approval and it will be available in February 2025.

After filing a new drug submission for its ustekinumab biosimilar PYZCHIVA (Janssen’s STELARA), Samsung commenced the ...

Mean duration of Crohn's disease was 7.4 years. Nearly half (48.5%) had previous biologic therapy failure, 45.7% had previous ...

Results of a Phase III study conducted by an international team of researchers reveal that mirikizumab is more effective and ...

Let's catch up on the latest news from the stock market. From significant investments to major deals, order wins, auto sales, and fund raising, here’s a quick look at which stocks will be in focus in ...

CSPC Pharmaceutical Group (HK:1093) has released an update. CSPC Pharmaceutical Group has announced that its subsidiary’s biologic license ...